Canada [français] | Apotex Worldwide

About Us

For Media Inquiries, Please Contact:

Apotex Inc.
150 Signet Drive
North York,
ON, M9L 1T9
Canada
Email

Press Center

August 9, 2023

Voluntary Recall of seven (7) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard)
August 9, 2023

Voluntary Recall of three (3) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
April 3, 2023

SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
February 1, 2023

Voluntary Recall of one (1) lot of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg - Lot PY1904
December 16, 2022

Accessa becomes the patient support program manager for Apotex Inc.'s Apo-Deferasirox™ and Apo-Deferasirox (Type J)™ products.
September 28, 2022

SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals

Investment from SK Capital to support Apotex’s next phase of growth and continued innovation for patient affordability
July 27, 2022

Voluntary Recall of four (4) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg
July 20, 2022

First Generic Alternative to Eliquis® Now Available in Canada

Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-Apixaban^™ tablets, Canada's first generic alternative to Eliquis^®
May 17, 2022

Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
April 26, 2022

Voluntary Recall of five (5) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg.
January 19, 2022

Voluntary Recall of one (1) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1832.
November 30, 2021

Canada-Wide Contest Recognizes the Impact of Pharmacy Professionals on Patient Care
November 9, 2021

Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada
September 30, 2021

VOLUNTARY NATIONWIDE RECALL: ONE LOT OF Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) 0.150 mg / 0.030 mg DUE TO POSSIBILITY OF ONE PLACEBO PILL IN PLACE OF AN ACTIVE PILL
September 27, 2021

Canadian Cancer Patients Have New Affordable Treatment Option
September 1, 2021

CANADIAN-MADE GENERIC OPTION TO TREAT MULTIPLE MYELOMA NOW AVAILABLE
April 29, 2021

Voluntary Recall of one (1) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1831.
April 15, 2021

GOVERNMENT OF CANADA AWARDS APOTEX INC. A SIGNIFICANT CONTRACT TO SUPPLY A SAFETY NET OF ADDITIONAL DEXAMETHASONE IN CANADA
April 13, 2021

Voluntary Recall of one (1) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot RF0410.
June 12, 2020

Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.